Literature DB >> 32613401

Stratification of cystic renal masses into benign and potentially malignant: applying machine learning to the bosniak classification.

Nityanand Miskin1, Lei Qin2, Shanna A Matalon3, Sree H Tirumani4, Francesco Alessandrino3,2, Stuart G Silverman3, Atul B Shinagare3,2.   

Abstract

PURPOSE: To create a CT texture-based machine learning algorithm that distinguishes benign from potentially malignant cystic renal masses as defined by the Bosniak Classification version 2019.
METHODS: In this IRB-approved, HIPAA-compliant study, 4,454 adult patients underwent renal mass protocol CT or CT urography from January 2011 to June 2018. Of these, 257 cystic renal masses were included in the final study cohort. Each mass was independently classified using Bosniak version 2019 by three radiologists, resulting in 185 benign (Bosniak I or II) and 72 potentially malignant (Bosniak IIF, III or IV) masses. Six texture features: mean, standard deviation, mean of positive pixels, entropy, skewness, kurtosis were extracted using commercial software TexRAD (Feedback PLC, Cambridge, UK). Random forest (RF), logistic regression (LR), and support vector machine (SVM) machine learning algorithms were implemented to classify cystic renal masses into the two groups and tested with tenfold cross validations.
RESULTS: Higher mean, standard deviation, mean of positive pixels, entropy, skewness were statistically associated with the potentially malignant group (P ≤ 0.0015 each). Sensitivity, specificity, positive predictive value, negative predictive value, and area under curve of RF model was 0.67, 0.91, 0.75, 0.88, 0.88; of LR model was 0.63, 0.93, 0.78, 0.86, 0.90, and of SVM model was 0.56, 0.91, 0.71, 0.84, 0.89, respectively.
CONCLUSION: Three CT texture-based machine learning algorithms demonstrated high discriminatory capability in distinguishing benign from potentially malignant cystic renal masses as defined by the Bosniak Classification version 2019. If validated, CT texture-based machine learning algorithms may help reduce interreader variability when applying the Bosniak classification.

Entities:  

Keywords:  Bosniak classification v2019; Cystic renal mass; Machine learning; Texture analysis

Mesh:

Year:  2020        PMID: 32613401     DOI: 10.1007/s00261-020-02629-w

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  32 in total

1.  A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.

Authors:  Hendrik Van Poppel; Luigi Da Pozzo; Walter Albrecht; Vsevolod Matveev; Aldo Bono; Andrzej Borkowski; Marc Colombel; Laurence Klotz; Eila Skinner; Thomas Keane; Sandrine Marreaud; Sandra Collette; Richard Sylvester
Journal:  Eur Urol       Date:  2010-12-22       Impact factor: 20.096

2.  Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis.

Authors:  Maxine Sun; Rodolphe Thuret; Firas Abdollah; Giovanni Lughezzani; Jan Schmitges; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Jean-Jacques Patard; Paul Perrotte; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

3.  Overdiagnosis and overtreatment in cancer: an opportunity for improvement.

Authors:  Laura J Esserman; Ian M Thompson; Brian Reid
Journal:  JAMA       Date:  2013-08-28       Impact factor: 56.272

4.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

5.  Defining, Estimating, and Communicating Overdiagnosis in Cancer Screening.

Authors:  Louise Davies; Diana B Petitti; Meghan Woo; Jennifer S Lin
Journal:  Ann Intern Med       Date:  2018-12-04       Impact factor: 25.391

6.  Bosniak Classification for Complex Renal Cysts Reevaluated: A Systematic Review.

Authors:  Ivo G Schoots; Keren Zaccai; Myriam G Hunink; Paul C M S Verhagen
Journal:  J Urol       Date:  2017-03-09       Impact factor: 7.450

7.  Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer.

Authors:  Hung-Jui Tan; Edward C Norton; Zaojun Ye; Khaled S Hafez; John L Gore; David C Miller
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

8.  A non-cancer-related survival benefit is associated with partial nephrectomy.

Authors:  Maxine Sun; Quoc-Dien Trinh; Marco Bianchi; Jens Hansen; Nawar Hanna; Firas Abdollah; Shahrokh F Shariat; Alberto Briganti; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2011-12-03       Impact factor: 20.096

9.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

10.  Risk factors for renal cysts.

Authors:  N Terada; Y Arai; N Kinukawa; K Yoshimura; A Terai
Journal:  BJU Int       Date:  2004-06       Impact factor: 5.588

View more
  4 in total

1.  The Bosniak Classification Gets Even Better.

Authors:  Peter L Choyke
Journal:  Radiology       Date:  2020-09-22       Impact factor: 11.105

Review 2.  Imaging Characterization of Renal Masses.

Authors:  Carlos Nicolau; Natalie Antunes; Blanca Paño; Carmen Sebastia
Journal:  Medicina (Kaunas)       Date:  2021-01-08       Impact factor: 2.430

3.  Prediction of premature ventricular complex origins using artificial intelligence-enabled algorithms.

Authors:  Tomofumi Nakamura; Yasutoshi Nagata; Giichi Nitta; Shinichiro Okata; Masashi Nagase; Kentaro Mitsui; Keita Watanabe; Ryoichi Miyazaki; Masakazu Kaneko; Sho Nagamine; Nobuhiro Hara; Tetsumin Lee; Toshihiro Nozato; Takashi Ashikaga; Masahiko Goya; Tetsuo Sasano
Journal:  Cardiovasc Digit Health J       Date:  2020-11-28

4.  Development and Validation of a Random Forest Risk Prediction Pneumothorax Model in Percutaneous Transthoracic Needle Biopsy.

Authors:  Hong Lin Wu; Gao Wu Yan; Li Cheng Lei; Yong Du; Xiang Ke Niu; Tao Peng
Journal:  Med Sci Monit       Date:  2021-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.